Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Capital Expenditures (2023 - 2025)

Immunome (IMNM) has disclosed Capital Expenditures for 3 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 360.32% year-over-year to $8.4 million, compared with a TTM value of $9.7 million through Dec 2025, up 245.15%, and an annual FY2025 reading of $9.7 million, up 245.15% over the prior year.
  • Capital Expenditures was $8.4 million for Q4 2025 at Immunome, up from -$39000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $8.4 million in Q4 2025 and bottomed at -$3.2 million in Q4 2024.
  • Average Capital Expenditures over 3 years is $1.1 million, with a median of $217000.0 recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 2180.09% in 2024, while the deepest fall reached 2846.36% in 2024.
  • Year by year, Capital Expenditures stood at -$110000.0 in 2023, then crashed by 2846.36% to -$3.2 million in 2024, then soared by 360.32% to $8.4 million in 2025.
  • Business Quant data shows Capital Expenditures for IMNM at $8.4 million in Q4 2025, -$39000.0 in Q3 2025, and $695000.0 in Q2 2025.